Thus, treatment of head and neck squamous cell carcinoma and non-small cell lung cancer cells with the fully humanized anti-IGF-IR monoclonal antibody (MAb), Cixutumumab, induced Akt and mammalian target of rapamycin (mTOR) activation, resulting in EGFR, Akt1, and survivin synthesis and EGFR pathway activation. This evidence concerns the gene IGF1R and non-small cell lung carcinoma.